- In October 2024, Medtronic announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter for treating persistent atrial fibrillation (AFib) and atrial flutter. With this approval, Medtronic becomes the first to offer two PFA technologies, enhancing treatment flexibility for physicians
- In November 2024, Johnson & Johnson MedTech, announced that the U.S. Food & Drug Administration (FDA) has approved the VARIPULSE Platform for treating drug-resistant paroxysmal Atrial Fibrillation (AFib). This approval positions the company to expand its portfolio of innovative solutions, enhancing its market leadership and offering new therapeutic options to patients with challenging AFib cases
- In May, Biosense Webster, Inc., announced the launch of CARTO 3 System Version 8, the newest iteration of its advanced three-dimensional (3D) heart mapping system used in cardiac ablation procedures. This launch strengthens the company’s position as a pioneer in cardiac technology, offering enhanced capabilities that improve procedural precision and patient outcomes, further solidifying its leadership in the cardiovascular space
